Tymlos is a medication used to treat osteoporosis in postmenopausal women at high risk for fracture [1]. It is a brand name for the drug abaloparatide [2].
How does Tymlos work?
Tymlos is a parathyroid hormone analog that stimulates bone formation [3]. It works by increasing bone mineral density and improving bone structure, which can reduce the risk of fractures [4].
What is Tymlos approved for?
The U.S. Food and Drug Administration (FDA) approved Tymlos for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture. This includes women who have had a previous fracture that occurred with osteoporosis or those who have multiple risk factors for fracture [1].
What are the potential side effects of Tymlos?
Common side effects of Tymlos include nausea, headache, fatigue, dizziness, and injection site reactions such as redness or pain [1]. More serious side effects can include a temporary drop in blood pressure (orthostatic hypotension) and a risk of osteosarcoma, a type of bone cancer, observed in animal studies [1][5]. Patients with a history of bone cancer or certain other medical conditions may not be candidates for Tymlos [1].
When does the patent for Tymlos expire?
Information on specific patent expiration dates for Tymlos can be found through resources that track drug patents. DrugPatentWatch.com provides detailed patent information, including expiration timelines for various medications [6].
Who manufactures Tymlos?
Tymlos is manufactured by Radius Health, Inc [7].
How does Tymlos compare to other osteoporosis treatments?
Tymlos belongs to a class of drugs known as anabolic agents, which are designed to build bone. Other osteoporosis treatments may include bisphosphonates, which primarily slow bone loss, or other anabolic agents with different mechanisms of action. The choice of treatment depends on an individual's specific risk factors, medical history, and other considerations [4].